Generic substitution of lamotrigine among medicaid patients with diverse indications: A cohort-crossover study

CNS Drugs

Volumn 26, Issue 8, 2012, Pages 707-716

  Hartung, Daniel M ^a   Middleton, Luke ^a   Svoboda, Leanne ^a   McGregor, Jessina C ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Antiepileptic drugs; Bipolar disorders; Branded drugs; Epilepsy; Generic drugs; Lamotrigine; Migraine; Pain

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; GENERIC DRUG; LAMOTRIGINE; MOOD STABILIZER; NEUROLEPTIC AGENT;

ANTICONVULSANT THERAPY; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; DEPRESSION; DRUG INDICATION; DRUG USE; EMERGENCY CARE; EMERGENCY WARD; EPILEPSY; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; MIGRAINE; PAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTICONVULSANTS; COHORT STUDIES; CROSS-OVER STUDIES; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUGS, GENERIC; EPILEPSY; HOSPITALIZATION; HUMANS; MEDICAID; RETROSPECTIVE STUDIES; TRIAZINES; UNITED STATES;

EID: 84863648813     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11634260-000000000-00000     Document Type: Article

References (37)

1. Haas JS, Phillips KA, Gerstenberger EP, et al. Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000. Ann Intern Med 2005; 142: 891-7
2. Shrank WH, Choudhry NK, Liberman JN, et al. The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money. Health Aff (Millwood) 2011; 30: 1351-7
3. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003; 25: 2875-90
4. Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009; 43: 1583-97
5. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease. JAMA 2008; 300: 2514-26
6. Besag FMC. Generic antiepileptic drugs and increased health care utilization. Neurology 2010; 74: 1562-3
7. Kesselheim AS. The backlash against bioequivalence and the interchangeability of brand-name and generic drugs. CMAJ 2011; 183: 1350-1
8. Bialer M, Midha KK. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia 2010; 51: 941-50
9. Mintzer S. Brand spanking? The presumptive risks of generic antiepileptic drugs. Epilepsy Curr 2011; 11: 54-5
10. Berg MJ. What's the problem with generic antiepileptic drugs? A call to action. Neurology 2007; 68: 1245-6
11. Privitera MD. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr 2008; 8: 113-7
12. Moore N, Berdai D, Begaud B. Are generic drugs really inferior medicines? Clin Pharmacol Ther 2010; 88: 302-4
13. Krauss GL, Caffo B, Chang Y-T, et al. Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol 2011; 70: 221-8
14. Liow K, Barkley GL, Pollard JR, et al. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007; 68: 1249-50
15. Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010; 70: 605-21
16. Yamada M, Welty TE. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann Pharmacother 2011; 45: 1406-15
17. Desmarais JE, Beauclair L, Margolese HC. Switching from brand-name to generic psychotropic medications: a literature review. CNS Neurosci Ther 2011; 17: 750-60
18. Makus KG,McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 2007; 29: 334-41
19. Savica R, Beghi E,Mazzaglia G, et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. Eur J Neurol 2007; 14: 1317-21
20. Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 2007; 6: 465-8
21. Chen H, Deshpande AD, Jiang R, et al. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf 2005; 14: 629-38
22. Chen H, Reeves JH, Fincham JE, et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry 2006; 67: 972-82
23. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-53
24. Maclure M, Mittleman MA. Should we use a case-crossover design? Ann Rev Public Health 2000; 21: 193-221
25. Goldsmith DR, Wagstaff AJ, Ibbotson T, et al. Spotlight on lamotrigine in bipolar disorder. CNS Drugs 2004; 18: 63-7
26. Rascati KL, Richards KM, Johnsrud MT, et al. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy 2009; 29: 769-74
27. Zachry III WM, Doan QD, Clewell JD, et al. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009; 50: 493-500
28. Hansen RN, Campbell JD, Sullivan SD. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav 2009; 15: 481-5
29. Devine ST, Weisbart E, Barron J, et al. Acute epilepsy exacerbations in patients switched between A-rated antiepileptic drugs. Curr Med Res Opin 2010; 26: 455-63
30. LeLorier J, Sheng Duh M, Emmanuel Paradis P, et al. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Res Opin 2008; 24: 1069-81
31. LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008; 70: 2179-86
32. Duh MS, Paradis PE, Latremouille-Viau D, et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009; 72: 2122-9
33. Labiner DM, Paradis PE, Manjunath R, et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 2010; 74: 1566-74
34. Erickson SC, Le L, Ramsey SD, et al. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Epilepsia 2011; 52: 1365-71
35. Gagne JJ, Avorn J, Shrank WH, et al. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther 2010; 88: 347-53
36. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clinl Epidemiol 2005; 58: 323-37
37. Levine M, Ensom MH. Post hoc power analysis: an idea whose time has passed? Pharmacotherapy 2001; 21: 405-9